American Journal of Obstetrics & Gynecology
Volume 198, Issue 1 , Pages 32.e1-32.e7 , January 2008

Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations

Presented in part at the 43rd Annual Meeting of the Association of Reproductive Health Professionals, hosted with the Planned Parenthood Federation of America and the Society of Family Planning, La Jolla, CA, Sept. 6-9, 2006.

  • Bryna Harwood, MD, MS

      Affiliations

    • Department of Obstetrics and Gynecology, University of Illinois at Chicago College of Medicine, Chicago, IL
    • ,
  • Leslie A. Meyn, MS

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, and Magee-Womens Research Institute, Pittsburgh, PA
    • ,
  • Susan A. Ballagh, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA
    • ,
  • Elizabeth G. Raymond, MD, MPH

      Affiliations

    • Family Health International, Research Triangle Park, Durham, NC
    • ,
  • David F. Archer, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA
    • ,
  • Mitchell D. Creinin, MD

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, and Magee-Womens Research Institute, Pittsburgh, PA

Received 18 May 2006 ,Revised 19 January 2007 ,Accepted 12 May 2007.

References 

  1. Trussell J. Contraceptive failure in the United States. Contraception. 2004;70:89–96
  2. Henshaw S. Unintended pregnancy in the United States. Fam Plann Persp. 1998;30:24–29
  3. Mosher W, Martinez G, Chandra A, Abma J, Willson S. Use of contraception and use of family planning services in the United States: 1982-2002. Hyattsville, MD: National Center for Health Statistics; 2004;
  4. Niruthisard S, Roddy RE, Chutivongse S. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991;18:176–179
  5. Rustomjee R, Abdool Karim Q, Abdool Karim SS, Laga M, Stein Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS. 1999;13:1511–1515
  6. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993;4:165–170
  7. WHO. Manual for the standardization of colposcopy for the evaluation of vaginally administered product. Geneva: World Health Organization Global Programme on AIDS; 1995;WHO/GPA/RID/95.10
  8. Raymond EG, Lien Chen P, Luoto J Spermicide Trial Group. Contraceptive effectiveness and Safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol. 2004;103:430–439
  9. CONRAD/WHO. Manual for the standardization of colposcopy for the evaluation of vaginal products, update 2000. Geneva: CONRAD/WHO; 2000;CONRAD/2000.1, WHO/RHR/00.11.
  10. Hardin JW, Hilbe JM. Generalized estimating equations. Boca Raton, FL: Chapman & Hall/CRC; 2003;
  11. Kilmarx PH, Limpakarnjanarat K, Supawitkul S, et al. Mucosal disruption due to use of a widely-distributed commercial vaginal product: potential to facilitate HIV transmission. AIDS. 1998;12:767–773
  12. Schreiber CA, Meyn LA, Creinin MD, Barnhart KT, Hillier SL. Effects of long-term use of nonoxynol-9 on vaginal flora. Obstet Gynecol. 2006;107:136–143
  13. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers (COL-1492 Phase II Study Group). AIDS. 2000;14:85–88
  14. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:327–331
  15. Mauck CK, Baker JM, Barr SP, Abercrombie TJ, Archer DF. A phase I comparative study of contraceptive vaginal films containing benzalkonium chloride and nonoxynol-9 (Postcoital testing and colposcopy). Contraception. 1997;56:89–96
  16. Mauck CK, Baker JM, Barr SP, Johanson WM, Archer DF. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9: postcoital testing and colposcopy. Contraception. 1997;56:97–102
  17. Poindexter AN, Levine H, Sangi-Haghpeykar H, Frank ML, Grear A, Reeves KO. Comparison of spermicides on vulvar, vaginal, and cervical mucosa. Contraception. 1996;53:147–153
  18. Watts DH, Rabe L, Krohn MA, Aura J, Hillier SL. The effects of three nonoxynol-9 preparations on vaginal flora and epithelium. J Infect Dis. 1999;180:426–437
  19. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 1998;12:433–437
  20. Ladipo OA, De Castro MP, Filho LC, et al. A new vaginal antimicrobial contraceptive formulation: phase I clinical pilot studies. Contraception. 2000;62:91–97
  21. Joshi S, Joglekar N, Ghate M, et al. Phase I safety and preliminary acceptability of nonoxynol-9 vaginal pessary as a vaginal microbicide in low risk women in Pune, India. Indian J Med Res. 2003;117:152–157
  22. Creatsas G, Elsheikh A, Colin P. Safety and tolerability of the new contraceptive sponge Protectaid. Eur J Contracep Reprod Health Care. 2002;7:91–95

 Reprints not available from the authors.

 Funded by Family Health International, Durham, NC, with federal funds from the National Institute of Child Health and Human Development, NIH, under contract number N01-HD-7-3271, and by NIH General Clinical Research Center Grant M01RR000056 at the University of Pittsburgh.

 Cite this article as: Harwood B, Meyn LA, Ballagh SA, Raymond EG, Archer DF, Creinin MD. Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations. Am J Obstet Gynecol 2008;198:32.e1-32.e7.

PII: S0002-9378(07)00634-5

doi: 10.1016/j.ajog.2007.05.020

American Journal of Obstetrics & Gynecology
Volume 198, Issue 1 , Pages 32.e1-32.e7 , January 2008

Article Tools